Idecabtagene Vicleucel

AUSTIN, Texas and TOKYO, Dec. 29, 2025 /PRNewswire/ -- According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is projected to expand significantly to US$105.83 billion by 2033, registering a robust compound annual growth rate (CAGR) of 21.5% during the forecast period from 2025 to 2033. This exceptional growth trajectory reflects the accelerating transition of cell and gene therapies from experimental and early-stage clinical research into commercialized, life-altering treatments. Increasing regulatory approvals, expanding clinical pipelines, and rising investments in advanced therapeutic platforms are positioning cell and gene therapy as one of the most transformative segments within the global biopharmaceutical industry. Request Executive Sample | Cell and Gene Therapy Market Intelligence: Market Overview Cell and gene therapies represent a fundamental shift in how diseases are treated by addressing conditions at their biological root rather than managing symptoms. These approaches can be deployed independently or combined to create gene-modified cell therapies, offering unprecedented therapeutic potential. In combined approaches, a patient's cells are genetically modified through gene therapy techniques and then reintroduced into the body as a cell therapy. One of the most prominent examples is CAR-T cell therapy, where a patient's T cells are engineered to recognize and destroy cancer cells before being reinfused. This approach has demonstrated remarkable success in oncology and continues to expand into additional disease indications. Both cell and gene therapies are increasingly being explored for chronic, inherited, and life-threatening diseases that have limited or no effective treatment options. Their ability to provide long-term or potentially curative outcomes has significantly increased interest from healthcare providers, regulators, and investors worldwide. Market demand is being fueled by a growing number of therapy approvals, a rapidly expanding clinical development pipeline, and rising recognition of the unmet medical needs these therapies can address. Clinical Pipeline Momentum According to the American Society of Cell and Gene Therapy, the sector maintained strong momentum into early 2024, with several notable therapy approvals and sustained growth across all stages of clinical development. Currently, more than 4,000 gene, cell, and RNA-based treatments are in research and development globally. The clinical pipeline has expanded significantly across all phases, with Phase I trials experiencing the highest growth, increasing by approximately 11%. This surge highlights the industry's strong innovation engine and underscores the long-term commercial potential of next-generation therapies entering early-stage development. Market Dynamics Drivers: Advancements in Delivery Vectors One of the most significant growth drivers in the cell and gene therapy market is the increasing utilization of advanced delivery vectors. These vectors are essential for transporting genetic material-DNA or RNA-into target cells safely and efficiently. Traditional delivery systems have limitations related to targeting accuracy, immune response, and dosage efficiency. As a result, next-generation viral and non-viral vectors are being developed to improve therapeutic outcomes while reducing adverse immune reactions. Enhanced delivery systems can also lower dosage requirements, improving both safety and cost-effectiveness. In May 2023, AGC Biologics introduced its BravoAAV and ProntoLVV viral vector platforms, offering faster, scalable, and reproducible production under Good Manufacturing Practice (GMP) conditions. These platforms are designed to support both clinical and commercial-scale manufacturing. Similarly, in May 2024, Charles River Laboratories International, Inc. launched reference materials for adeno-associated virus (AAV) and lentiviral vector (LVV) portfolios to streamline cell and gene therapy research and enable smoother transitions to GMP-quality production. Restraints: High Development and Manufacturing Costs Despite strong growth prospects, high development costs and complex manufacturing processes remain significant restraints for the cell and gene therapy market. Production requires specialized cleanroom facilities, highly skilled personnel, and strict adherence to regulatory standards. Many therapies-particularly autologous treatments such as CAR-T-must be customized for each individual patient, substantially increasing production time and cost. Manufacturing costs for CAR-T therapies can exceed US$100,000 per patient, while certain gene therapies, such as one-time treatments for rare genetic diseases, can cost over US$2 million per patient. These high costs create challenges related to reimbursement, scalability, and patient access. In addition, the production of viral vectors and specialized raw materials is both capital- and time-intensive, with limited suppliers further increasing expenses. According to simulations by the National Institutes of Health (NIH), annual spending on gene therapies could reach approximately US$20.4 billion, even under conservative assumptions. Purchase Corporate License | Cell and Gene Therapy Market Intelligence: Market Segmentation Analysis By Therapy Type The global cell and gene therapy market is segmented into cell therapy and gene therapy, with cell therapy accounting for the dominant share. In 2024, the cell therapy segment held approximately 61.2% of the global market share. The segment demonstrated strong growth, reaching US$13.39 billion in 2022 and increasing further to US$14.66 billion in 2023. Cell therapies have gained widespread adoption due to their strong clinical success, particularly in oncology and regenerative medicine. CAR-T therapies and stem cell-based treatments have shown high efficacy, accelerating approvals and market uptake. A notable milestone occurred in April 2024, when India launched its first indigenously developed CAR-T cell therapy, developed by the Indian Institute of Technology (IIT) Bombay and Tata Memorial Centre. The therapy is being offered at nearly one-tenth of the global cost, significantly improving accessibility and highlighting the role of innovation in cost reduction. Substantial funding from governments and research institutions continues to support cell therapy development. For example, researchers at the University of California, San Francisco (UCSF) initiated a clinical trial for a next-generation CAR-T therapy targeting glioblastoma, supported by an US$11 million grant from the California Institute for Regenerative Medicine (CIRM). Geographical Analysis North America North America dominates the global cell and gene therapy market, accounting for approximately 43.7% of the total market share. The region recorded a market size of US$10.94 billion in 2022, which expanded to US$11.97 billion in 2023. The region's leadership is supported by a strong biotechnology ecosystem, advanced healthcare infrastructure, and the presence of leading academic research institutions. The United States, in particular, benefits from proactive regulatory frameworks that accelerate development and commercialization. The U.S. Food and Drug Administration (FDA) has introduced specialized pathways such as the Regenerative Medicine Advanced Therapy (RMAT) designation, which expedites the review of promising therapies. In August 2024, Ocugen, Inc. received FDA clearance to initiate an expanded access program for OCU400, a modifier gene therapy for retinitis pigmentosa, highlighting continued regulatory support for innovative treatments. Competitive Landscape The cell and gene therapy market features a combination of established pharmaceutical companies and innovative biotechnology firms. Leading players focus on expanding clinical pipelines, improving manufacturing capabilities, and forming strategic collaborations. Key Market Players Emerging players such as Editas Medicine, Intellia Therapeutics, Rocket Pharmaceuticals, Regenxbio, and Affinia Therapeutics are contributing to innovation through next-generation gene-editing and vector technologies. Novartis AG Key CGT products: Kymriah (CAR-T), Zolgensma (AAV gene therapy) Technology focus: CAR-T cell therapy, in-vivo AAV gene therapy Competitive positioning: Novartis is a first-mover and scale leader in CGT, with strong manufacturing capabilities, regulatory experience, and global commercialization across oncology and rare genetic diseases. Primary markets served: US, Europe, Japan, China Gilead Sciences, Inc. Key CGT products: Yescarta, Tecartus (CAR-T therapies) Technology focus: Autologous CAR-T cell therapy (via Kite Pharma) Competitive positioning: Gilead is a dominant CAR-T oncology player, focusing on hematological malignancies with continuous innovation in manufacturing efficiency and next-generation CAR designs. Primary markets served: US, Europe Bristol Myers Squibb Company Key CGT products: Breyanzi, Abecma (CAR-T therapies) Technology focus: CAR-T cell therapies for blood cancers Competitive positioning: BMS has built a robust CAR-T franchise through strategic acquisitions and partnerships, emphasizing differentiated safety profiles and broader patient eligibility. Primary markets served: US, Europe, Japan Vertex Pharmaceuticals Incorporated Key CGT products: Casgevy (exagamglogene autotemcel; gene-edited therapy, partnered) Technology focus: CRISPR/Cas9 gene editing (functional cure approach) Competitive positioning: Vertex is redefining CGT with curative, one-time gene-editing therapies, particularly in hemoglobinopathies, moving the market beyond symptomatic treatment. Primary markets served: US, Europe, select global markets Orchard Therapeutics Key CGT products: Libmeldy (ex-vivo gene therapy for metachromatic leukodystrophy) Technology focus: Ex-vivo autologous hematopoietic stem cell gene therapy Competitive positioning: Orchard is a pure-play rare pediatric gene therapy innovator, specializing in ultra-rare, life-threatening genetic disorders. Primary markets served: Europe, United States Krystal Biotech, Inc. Key CGT products: Vyjuvek (topical gene therapy for dystrophic epidermolysis bullosa) Technology focus: Redosable, non-invasive gene therapy platforms Competitive positioning: Krystal stands out for non-systemic, localized gene therapy delivery, significantly lowering safety and manufacturing complexity compared with systemic CGTs. Primary markets served: United States, Europe Request Customized Intelligence Aligned to Your Business Strategy: Recent Industry Developments The market continues to evolve through technological advancements and strategic initiatives: September 2024: CPC (Colder Products Company) launched a new aseptic micro-connector designed specifically for freeze cassettes used in cell and gene therapy processing. April 2024: Walgreens announced plans to work directly with drug manufacturers to expand patient access to cell and gene therapies through its specialty pharmacy division, including AllianceRx. May 2024: ProPharma, in partnership with Italy-based PBL, launched the Cell Factory Box (CF Box)-a fully automated system enabling decentralized CGT manufacturing in controlled environments. Conclusion The global cell and gene therapy market is entering a period of unprecedented growth, driven by rapid innovation, expanding clinical pipelines, and increasing regulatory support. While challenges related to cost, scalability, and manufacturing complexity persist, ongoing advancements in delivery vectors, automation, and decentralized production are expected to address many of these barriers. With strong momentum across research, development, and commercialization, cell and gene therapies are poised to redefine treatment paradigms and deliver long-term value to healthcare systems worldwide through 2033 and beyond. Related Report: Cell and Gene Therapy Manufacturing Services Market How Biopharma Is Scaling Viral Vector Capacity and Reducing Time-to-Market Gene Editing Tools Market Investment Opportunities Across CRISPR, TALEN, and Next-Generation Editing Platforms Gene Therapy Market Commercialization Challenges, Pricing Pressures, and Growth Opportunities Through 2033 Cancer Gene Therapy Market Pipeline Trends, Clinical Success Rates, and Competitive Positioning Japan Gene Therapy Market Regulatory Pathways, Market Entry Strategies, and Growth Potential Japan Cell Therapy Market Demand Drivers, Manufacturing Landscape, and Strategic Opportunities About DataM Intelligence DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations. To find out more, visit or follow us on Twitter, LinkedIn, and Facebook. Contact: Sai Kiran DataM Intelligence 4market Research LLP Ground floor, DSL Abacus IT Park, Industrial Development Area Uppal, Hyderabad, Telangana 500039 USA: +1 877-441-4866 Email: [email protected] Logo: SOURCE DataM Intelligence 4 Market Research LLP 21% more press release views with Request a Demo

New York: A US judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi . While dismissing some claims, U.S. District Judge Jesse Furman in Manhattan said the plaintiff, UMB Bank , may pursue some claims on behalf of the shareholders, including for Bristol Myers' alleged breach of contract and failure to act in good faith. Bristol Myers and lawyers for the Princeton, New Jersey-based company did not immediately respond to requests for comment. A lawyer for UMB declined to comment. The lawsuit arose from Bristol Myers' $80.3 billion purchase of Celgene in 2019. Bristol Myers agreed to pay shareholders who held "contingent value rights" (CVR) an extra $9 per share in cash if it won timely U.S. Food and Drug Administration approvals for Liso-cel, which is sold as Breyanzi , and the drugs Ozanimod and Ide-cel. UMB, in its role as a trustee, said Bristol Myers slow-rolled the process by not using "diligent efforts" to win approvals, and wrongly delisted the CVRs from the New York Stock Exchange before holders could enforce their rights. Bristol Myers won FDA approval for Breyanzi to treat non-Hodgkin lymphoma on February 5, 2021, five weeks after the relevant deadline. In a 24-page decision, Furman said UMB had legal standing to sue, after addressing concerns he raised in a September 2024 dismissal of its earlier lawsuit. The judge also rejected Bristol Myers' claim that its alleged lack of diligence did not trigger an "event of default," and said a jury should decide whether Bristol Myers breached an implied agreement to act in good faith by delisting the CVRs. Furman gave Bristol Myers three weeks to formally respond to UMB's claims. (Reporting by Jonathan Stempel in New York; Editing by Rod Nickel)